Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

Marchetti, Tess; Cohen, Marie; Moerloose, Philippe de

doi:10.1155/2013/159124

Cited by 34 publications

(34 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is evidence that APS is the most frequently treatable acquired cause during pregnancy [14], although it is known that the classic form and the obstetric one have different rates of thrombosis [15], response to treatment [16] or follow-up [17]. Those incomplete forms (by meeting neither the clinical nor the laboratory criteria) represent a special challenge for the clinician [18], as there is increasing evidence that patients with low aPL titers can experience poor pregnancy outcomes similarly to high-titer patients [19].…”

Section: Introductionmentioning

confidence: 99%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

115

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Alijotas‐Reig¹,

Esteve-Valverde

Ferrer‐Oliveras³

et al. 2019

Autoimmunity Reviews

115

View full text Add to dashboard Cite

show abstract

“…Antiphospholipid syndrome is linked to both VTE risk and placental insufficiency, leading to a preterm delivery according to the current diagnostic criteria. 19 We were unable to assess the role of antiphospholipid antibodies as a mediating factor in our sample of term births, because a specific ICD-9-CM code does not exist. Furthermore, we observed a very low prevalence of ICD-9-CM codes for systemic lupus erythematosus (0.1% among controls), an important cause of secondary antiphospholipid syndrome, suggesting a minor mediating role or a partial capture of this diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Association Between Newborn Birth Weight and the Risk of Postpartum Maternal Venous Thromboembolism

et al. 2015

View full text Add to dashboard Cite

Background-Postpartum venous thromboembolism (VTE) is a potentially fatal and preventable event leading to substantial short-and long-term morbidity. We sought to evaluate whether the delivery of term newborns of low or high birth weight was associated with greater risks of VTE. Methods and Results-In a population-based case-control study conducted in Washington State from 1987 through 2011, cases of hospitalized VTE within 3 months of delivery were identified by using selected International Classification of Diseases, Ninth Revision, Clinical Modification codes. Controls were randomly selected postpartum women without VTE, matched on birth year. Birth weight and other maternal and pregnancy characteristics were extracted from birth certificate data. Among term live singleton deliveries, we compared the risk of VTE for mothers of newborns of low and high birth weights (<2500 g and >4000 g, respectively) versus mothers of newborns of normal birth weight (2500-4000 g). Logistic regression models were adjusted for maternal age, race, education, body mass index, parity, delivery methods, gestational length, smoking, gestational diabetes mellitus, and preeclampsia. Patients with VTE (n=547) were older, had a higher body mass index, and experienced more pregnancy-related complications than controls (n=9482).In comparison with mothers of newborns with normal birth weight, mothers of newborns with low birth weight had a 3-fold increased risk of VTE, which persisted after multivariable adjustment (odds ratio, 2.98; 95% confidence interval, 1.80-4.93). Mothers of newborns with high birth weight had only a slightly increased risk of VTE, which was attenuated after multivariable adjustment (odds ratio, 1.26; 95% confidence interval, 0.99-1.61). Conclusions-The delivery of a newborn with low birth weight is associated with a 3-fold increased risk of maternal postpartum VTE. This should be considered when assessing VTE risk at delivery.

show abstract

“…29 Nonsteroidal anti-inflammatory drugs (NSAIDs) may inhibit blastocyst implantation and lead to subsequent miscarriage. 30 NSAIDs can also lead to premature closure of the ductus arteriosus, particularly if administered after 32 weeks' gestation.…”

Section: Antiplatelet Therapy In Stemi During Pregnancy 321 | Aspmentioning

confidence: 99%

ST‐elevation acute myocardial infarction in pregnancy: 2016 update

Ismail

Wong

Rajan

et al. 2017

Clinical Cardiology

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) during pregnancy or the early postpartum period is rare, but can be devastating for both the mother and the fetus. There have been major advances in the diagnosis and treatment of acute coronary syndromes in the general population, but there is little consensus on the approach to diagnosis and treatment of pregnant women. This article reviews the literature relating to the pathophysiology of AMI in pregnant patients and the challenges in diagnosis and treatment of ST-elevation myocardial infarction (STEMI) in this unique population. From a cardiologist, maternal-fetal medicine specialist, and anesthesiologist's perspective, we provide recommendations for the diagnosis and management of STEMI occurring during pregnancy.

show abstract

Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

Cited by 34 publications

References 68 publications

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Association Between Newborn Birth Weight and the Risk of Postpartum Maternal Venous Thromboembolism

ST‐elevation acute myocardial infarction in pregnancy: 2016 update

Contact Info

Product

Resources

About